Drug Profile
CP 64131
Latest Information Update: 23 Jul 2002
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action P38 mitogen-activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 18 Dec 1998 New profile
- 18 Dec 1998 Preclinical development for Immunological disorders in USA (Unknown route)